[212Pb]VMT-α-NET (SSTR2-targeted alpha therapy) shows 39% ORR with clean early safety in PRRT-naïve NETs

[212Pb]VMT-α-NET is a SSTR2-targeted radiopharmaceutical that delivers the alpha-emitter lead-212 to SSTR2+ neuroendocrine tumors. In the Phase 1/2a dose-finding trial (NCT05636618) in well-differentiated unresectable/metastatic NETs that were PRRT-naïve and had progressed after ≥1 prior systemic therapy, 56 patients were treated across 2.5mCi (n=2), 5mCi (n=46), and 6mCi (n=8) cohorts; in the efficacy-evaluable set (n=25; cohort 1 + first half of cohort 2), investigator-assessed ORR was 39% (9/23; 8 confirmed) at 5mCi, and 19/25 had no progression at the 10-Dec-2025 data cutoff (median follow-up 49 weeks). Safety across all treated patients (n=56) looked unusually benign for radiopharmaceutical therapy—no DLTs, no grade 5 AEs, no treatment-related discontinuations, and no clinically significant treatment-related myelosuppression or serious renal complications—while historical SOC options after progression (everolimus, sunitinib; and in midgut NET, ^177Lu-DOTATATE where median PFS was ~28.4 months in NETTER-1) typically deliver low RECIST response rates with non-trivial chronic toxicity, making a ~39% ORR signal potentially differentiating if it holds with mature follow-up.